Pharmaceutical companies and Asthma UK have matched the £4.8million investment made by the UK Medical Research Council in an innovative new research programme, 'the United Kingdom Refractory Asthma Stratification Programme' (RASP-UK). RASP-UK aims to transform the way severe asthma is diagnosed and managed and to pave the way for the development of new treatments.
RASP-UK is being driven by a coalition between academics, NHS Trusts, the MRC, pharmaceutical companies, Vitalograph and several other partners including Asthma UK and the British Thoracic Society (BTS). Leading the initiative is Professor Liam Heaney, Professor of Respiratory Medicine at Queen's University Belfast.
The objective of the programme is to tackle the challenge of severe, poorly controlled asthmatics who fail to respond to incremental increases in currently available therapies. Such patients account for half the burden of asthma on healthcare resources.
In seeking to develop a more personalised approach to delivering available treatments and in researching new potential drug therapies, the use of objective serial measurements, home monitoring with centralised data collection and inhaler device compliance technology is vital and it is this area of expertise that Vitalograph will provide.
Bernard Garbe, Managing Director of Vitalograph, said
We are delighted to collaborate on an initiative designed to deliver better outcomes for those with poorly controlled asthma and to help push back the boundaries of possibility in the treatment of this life-threatening condition.